Skip to main content
. 2020 Feb 22;12(2):135. doi: 10.3390/toxins12020135

Table 1.

Patient characteristics.

Variable Total
(n = 75)
Age (years) 68.0 ± 15.3
Male (n; %) 43; 57.3
BMI (kg/m2) 26.1 ± 5.1
Dialysis vintage (months) 16.0 [9.0; 39.0]
Type of dialysis
Hemodialysis (n; %) 31; 41.3
Hemodiafiltration (n; %) 44; 58.7
Medication taken on a daily basis (n) 13.0 ± 3.9
Davies comorbidity score (0–7) 2.0 ± 1.3
Comorbidities
Diabetes (n; %) 35; 46.7
CVD (n; %) 54; 72.0
Neuropathy (n; %) 20; 26.7
Retinopathy (n; %) 24; 32.0
Respiratory disorders (n; %) 21; 28.0
Musculoskeletal disorders (n; %) 28; 37.3
Etiology of chronic kidney disease
Glomerulonephritis (n; %) 12; 16.0
Hematologic malignancies (n; %) 2; 2.7
Interstitial nephropathy (n; %) 7; 9.3
Diabetic nephropathy (n; %) 19; 25.3
Hypertension, angiosclerosis or unknown (n; %) 31; 41.4
ADPKD (n; %) 4; 5.3
Hemoglobin (g/dL) 11.1 ± 1.5
CRP (mg/L) 3.6 [2.5; 10.0]
Total serum protein (g/L) 65.0 ± 6.2
Anion gap (mEq/L) 12.0 [11.0; 19.1]
Quadriceps force (N) 186 ± 73
Patients with pathological quadriceps force (n; %) 68; 90.7
Handgrip force (kg) 30.0 ± 11.1
Patients with pathological handgrip force (n; %) 20; 26.7
Tinetti (/12) 11.0 [6.0; 12.0]
Patients at increased risk of falls (n; %) 35; 46.7
Sit-to-Stand (s) 18.0 [12.0; 50.0]
Patients at increased risk of falls (n; %) 47; 62.7
FICSIT (/28) 16.0 [10.0; 22.0]
6MWT (meters) 255 [110; 420]
Patients with pathological 6MWT (n; %) 65; 86.7
Patients scoring < 300 m on 6MWT (n; %) 43; 57.3

Values are expressed as mean ± SD, median [interquartile range] or as frequency (number; percentage). Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; CRP, C-reactive protein, CVD, cardiovascular disease; FICSIT, Frailty and Injuries Cooperative Studies of Intervention Technique-4; 6MWT, six-minute walking test.